Keywords: Novo Nordisk, Victoza, Liraglutide, Obesity trial

Novo Nordisk to re-initiate Phase III development of liraglutide for obesity

Article | 23 June 2010

Print This

Danish insulin giant Novo Nordisk has decided to re-initiate the global Phase III development program of its diabetes drug of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in